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Introduction
============

Gastroparesis is a disorder of delayed gastric emptying that commonly presents with nausea, vomiting, abdominal bloating and early satiety. Although the majority of gastroparesis cases are idiopathic or secondary to diabetic and post-surgical etiologies, a rare etiology of gastroparesis is paraneoplastic syndrome. This is most commonly seen in pancreatic, ovarian, gallbladder, lung, and soft tissue cancers \[[@REF1], [@REF2]\]. Paraneoplastic gastroparesis (PG) is an important diagnosis for two reasons: (1) the presentation of gastroparesis frequently precedes the diagnosis of the underlying malignancy and (2) treatment of the underlying malignancy may resolve the gastroparesis \[[@REF3]\]. The pathophysiology of PG is not well understood; however, studies have demonstrated an immune-mediated destruction of the interstitial cells of Cajal and neurons within the myenteric plexus as the primary histologic change in PG \[[@REF4], [@REF5]\]. Serologic testing for autoantibodies, specifically anti-neuronal nuclear autoantibodies type 1 (ANNA-1) or anti-Hu antibodies, which mediate the degeneration of neurons may aid in making the difficult diagnosis of PG. Herein, we report a case of PG with positive serologies as well as present a review of the literature on the subject.

Case presentation
=================

A 61-year-old African-American man presented with two months history of severe post-prandial nausea, vomiting and bloating. He also reported generalized fatigue, anorexia and unintentional weight loss of 20 pounds. He remained an active smoker with a 20-pack-year smoking history but denied any alcohol consumption or illicit substance use. His medications included ondansetron and pantoprazole tablets with minimal symptom relief. On admission, vital signs were only significant for slight tachycardia of 94 beats per minute. General physical examination revealed cachexia, temporal muscle wasting and clubbing of nails in both hands. The remainder of his examination was unremarkable. At this point, our differential diagnoses for his symptoms included gastrointestinal (GI), endocrine, metabolic, and psychiatric causes. From a GI perspective, we considered gastroparesis, gastric outlet obstruction, GI malignancy and cyclical vomiting syndrome.

Investigations

The following investigations were normal or negative: blood urea nitrogen, serum creatinine, serum potassium, serum total calcium, bilirubin, alanine aminotransferase, aspartate aminotransferase, serum lipase, urinalysis, chest X-ray and electrocardiogram. In addition, the patient had a computed tomography (CT) scan of the abdomen and pelvis on admission demonstrating residual food and fluid in his stomach despite fasting concerning for delayed gastric emptying. An esophagogastroduodenoscopy (EGD) was performed early in the admission and was seen to be normal. Scintigraphic gastric emptying studies were performed and gastric emptying time was calculated from anterior images acquired for approximately 90 minutes. The percentage of residual tracer within the stomach at two hours was 75% consistent with delayed gastric emptying or gastroparesis. A small bowel follow was also consistent with generalized GI hypo-motility disorder of unclear etiology.

He was screened for potential underlying causes for his gastroparesis. His fasting plasma glucose and hemoglobin A1c levels were normal ruling out diabetes mellitus. Hypothyroidism and connective tissue disorders were also ruled out by normal thyroid stimulating hormone levels and negative autoimmune panel, respectively. His neurological examination was entirely normal and had no history of recent viral illness or prior gastric surgery. None of his medications were particularly associated with a delay in gastric emptying. In view of his significant weight loss and active smoking a CT scan of the chest was performed which revealed a spiculated nodule sized 9 mm in right upper lobe of the lung (Figure [1](#FIG1){ref-type="fig"}) along with right hilar lymphadenopathy (Figure [2](#FIG2){ref-type="fig"}). A positron emission tomography (PET) scan was performed with hyper-metabolic activity in the right upper lobe nodule (Figure [3](#FIG3){ref-type="fig"}) and right hilar lymphadenopathy (Figure [4](#FIG4){ref-type="fig"}). Nodule resection and biopsy revealed a poorly differentiated non-small cell lung carcinoma (Figure [5](#FIG5){ref-type="fig"}) with no evidence of local or distal metastasis on PET scan and CT scan of the brain with intravenous contrast. Due to the concern for paraneoplastic origin of his gastroparesis further serological testing revealed positive anti-neuronal nuclear antibodies type 1 (Anti-Hu) and cytoplasmic purkinje cell antibodies (Anti-Yo).
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Treatment and outcome

The patient was diagnosed with a paraneoplastic gastroparesis secondary to occult non-small cell lung cancer. He was started on a chemotherapy combination of Carboplatin and Paclitaxel with a three-week course of local radiation therapy. Moreover, for the relief of his severe GI symptoms dietary modifications, pro-kinetic agents and psychological counselling were used with gradual clinical improvement observed on follow-up visits.

Discussion
==========

Gastroparesis cases can be attributed to idiopathic, diabetic, or post-surgical etiologies in majority of the cases. In the absence of these common etiologies, and with appropriate risk factor assessment, clinicians should consider a paraneoplastic syndrome causing gastroparesis \[[@REF1]\]. Early evaluation and diagnosis of malignancy can have a profound effect on the overall treatment course. Yet, the diagnosis of paraneoplastic gastroparesis can be extremely challenging. The Paraneoplastic Neurological Syndrome Euronetwork (PNSE) has established diagnostic criteria for paraneoplastic neurologic syndromes including paraneoplastic gastroparesis. Gastroparesis can be classified as definite paraneoplastic syndrome when there is presence of positive onco-neural antibodies or onset of symptoms is within five years of the development of cancer \[[@REF6]\]. PNSE recognizes that the onco-neural antibodies in their criteria are limited to those that are well-studied (anti-Hu antibody, anti-Yo antibody, anti-collapsin response mediator protein 5 antibody, anti-neuronal nuclear antibody type 2, anti-Ma2 antibody, anti-amphiphysin antibody). However, they concede that other antibodies could be used in the diagnosis once they are further characterized. In our study we identified four more antibodies (ganglionic acetylcholine receptor antibody, anti-ganglioside GM1 antibody, P/Q-type voltage-gated calcium channel antibody, N-type voltage-gated calcium channel antibody) that are known to target autonomic and motor neurons and are potential areas for further study to establish their utility in diagnosis of PG \[[@REF4], [@REF7]\]. Once the diagnosis of PG is made, the treatment (irrespective of etiology) is usually a combination of several recommendations: dietary modifications including frequent fiber intake, low-fat diet, frequent meals; daily use of pro-kinetic agents such as metoclopramide or erythromycin; and daily use of anti-emetics \[[@REF1], [@REF8]\]. In PG, interestingly, there is evidence that successful treatment of the primary malignancy may improve symptoms of gastroparesis \[[@REF3]\].

Literature review

To further investigate the association between various cancers and paraneoplastic gastroparesis and to find out the clinical utility of serological testing in the diagnosis of this complex and challenging clinical entity we conducted a literature search using the electronic database engines MEDLINE through PubMed, EMBASE, Ovid and Scopus from inception to December 2018. The combinations of keywords used were ("malignancy" or "cancer" or "carcinoma" or "paraneoplastic") and ("gastroparesis" or "hypo-motility"). The reference list of all eligible reports was reviewed to identify additional reports. Reports were excluded if (1) they were not written in English, (2) no malignancy was found in the reported patient or (2) reports were published as abstracts only. Eventually, 16 reports, including 22 cases, were identified as listed in Table [1](#TAB1){ref-type="table"}. Characteristics of the patient population are listed in Table [2](#TAB2){ref-type="table"}. Management and prognosis of the included patients are summarized in Table [3](#TAB3){ref-type="table"}.

###### Characteristics of included studies.

  ------------------------------------------ ------ ------------------------
  Study                                      Year   Country of Publication
  Gerl et al. \[[@REF9]\]                    1992   United States
  Kelly et al. \[[@REF10]\]                  2014   Ireland
  Moskovitz and Robb \[[@REF11]\]            2002   Canada
  Hejazi et al. \[[@REF12]\]                 2009   United States
  Vaidya et al. \[[@REF8]\]                  2014   United States
  Argyriou et al. \[[@REF13]\]               2012   United Kingdom
  Burger et al. \[[@REF14]\]                 2013   Netherlands
  Franco and Koulaeva \[[@REF15]\]           2014   Australia
  Pardi et al. \[[@REF4]\]                   2002   United States
  Ghoshal et al. \[[@REF16]\]                2005   India
  Bernardis et al. \[[@REF17]\]              1999   Switzerland
  Liang et al. \[[@REF18]\]                  1994   United States
  Lautenbach and Lichtenstein \[[@REF19]\]   1995   United States
  Nguyen-tat et al. \[[@REF3]\]              2008   Germany
  Caras et al. \[[@REF20]\]                  1996   United States
  Chinn and Schuffler \[[@REF5]\]            1988   United States
  ------------------------------------------ ------ ------------------------

###### Characteristics of patients in included studies.

SCLC: Small cell lung cancer; Anti-Hu: Anti-neuronal nuclear antibodies type 1; Anti-Yo: Cytoplasmic purkinje cell antibodies; ANNA-2: Anti-neuronal nuclear antibodies type 2; G-AchR antibody: Ganglionic acetylcholine receptor antibody; Anti-GM1 antibody: Anti ganglioside GM1 antibody; +ve: Positive; -ve: Negative.

  ------------------------------------------ ----- -------- --------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                      Age   Gender   Type of Cancer                    Time Elapsed between GI Symptoms and Cancer Diagnosis   Antineuronal Antibodies
  Gerl et al. \[[@REF9]\]                    53    F        Bronchial carcinoid               Four years after cancer diagnosis                       Not reported
  Kelly et al. \[[@REF10]\]                  69    F        SCLC                              One year prior to cancer diagnosis                      Anti-Hu -ve, Anti-Yo -ve
  Moskovitz and Robb \[[@REF11]\]            57    F        SCLC                              Six months prior to cancer diagnosis                    Anti-Hu +ve
  Hejazi et al. \[[@REF12]\]                 56    M        SCLC                              Six months prior to cancer diagnosis                    Anti-Hu +ve, ANNA-2 -ve
  Vaidya et al. \[[@REF8]\]                  87    M        Lung adenocarcinoma               Two weeks prior to cancer diagnosis                     Anti-Hu -ve, ANNA-2 -ve
  Argyriou et al. \[[@REF13]\]               70    F        SCLC                              Eight weeks prior to cancer diagnosis                   Not reported
  Burger et al. \[[@REF14]\]                 74    M        SCLC                              Eight months prior to cancer diagnosis                  Anti-Hu +ve
  Franco and Koulaeva \[[@REF15]\]           72    M        Pancreatic neuroendocrine tumor   One month after cancer diagnosis                        Not reported
  Pardi et al. \[[@REF4]\]                   68    M        SCLC                              Three months prior to cancer diagnosis                  Anti-Hu +ve, P/Q-type voltage-gated calcium channel antibody +ve, ANNA-2 -ve, N-type voltage-gated calcium channel antibody -ve, G-AchR antibody -ve
  Ghoshal et al. \[[@REF16]\]                55    F        Cholangiocarcinoma                Five months prior to cancer diagnosis                   Not reported
  Bernardis et al. \[[@REF17]\]              20    M        Leiomyosarcoma                    Four months prior to cancer diagnosis                   Not reported
  Liang et al. \[[@REF18]\]                  66    M        SCLC                              Seven months prior to cancer diagnosis                  Anti GM1 antibody +ve, Anti-Hu +ve
  Lautenbach and Lichtenstein \[[@REF19]\]   53    F        Leiomyosarcoma                    Two months prior to cancer diagnosis                    Not reported
  Nguyen-tat et al. \[[@REF3]\]              73    M        SCLC                              Four months prior to cancer diagnosis                   Anti-Hu +ve
  Caras et al. \[[@REF20]\]                  73    F        Pancreatic adenocarcinoma         One year prior to cancer diagnosis                      Not reported
  Chinn and Schuffler Case 1 \[[@REF5]\]     58    F        SCLC                              Nine months prior to cancer diagnosis                   Not reported
  Chinn and Schuffler Case 2 \[[@REF5]\]     58    F        SCLC                              Five months prior to cancer diagnosis                   Not reported
  Chinn and Schuffler Case 3 \[[@REF5]\]     72    M        SCLC                              Six months prior to cancer diagnosis                    Not reported
  Chinn and Schuffler Case 4 \[[@REF5]\]     69    F        Lung carcinoid                    One month prior to cancer diagnosis                     Not reported
  Chinn and Schuffler Case 5 \[[@REF5]\]     74    F        SCLC                              Four months prior to cancer diagnosis                   Not reported
  Chinn and Schuffler Case 6 \[[@REF5]\]     68    F        SCLC                              One month after cancer diagnosis                        Not reported
  Chinn and Schuffler Case 7 \[[@REF5]\]     62    M        SCLC                              26 months prior to cancer diagnosis                     Not Reported
  ------------------------------------------ ----- -------- --------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------

###### Management and prognosis of patients in included studies.

SCLC: Small cell lung cancer; TPN: Total parenteral nutrition; NJ tube: Nasojejunal tube; IV: Intravenous.

  ------------------------------------------ --------------------------------- ----------------------------------------------- ------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  Study                                      Type of Cancer                    Cancer Treatment                                GI Symptoms Treatment                             Prognosis
  Gerl et al. \[[@REF9]\]                    Bronchial carcinoid               Pneumonectomy and lymph node dissection         Prokinetics and TPN                               No clinical improvement. Patient passed away 10 months after the onset of GI symptoms.
  Kelly et al. \[[@REF10]\]                  SCLC                              Not a candidate for chemotherapy/radiotherapy   Prokinetics                                       Symptoms resolved with prokinetics.
  Moskovitz and Robb \[[@REF11]\]            SCLC                              Chemotherapy and radiotherapy                   Prokinetics and TPN                               No clinical improvement.
  Hejazi et al. \[[@REF12]\]                 SCLC                              Chemotherapy and radiotherapy                   Antibiotics and laxatives                         Symptoms improved after chemotherapy
  Vaidya et al. \[[@REF8]\]                  Lung adenocarcinoma               Not reported                                    Prokinetics                                       Symptoms improved with prokinetics.
  Argyriou et al. \[[@REF13]\]               SCLC                              Not reported                                    Prokinetics, TPN, gastric pacing                  Symptoms improved with gastric pacing. Patient passed away one week afterwards from respiratory tract infection.
  Burger et al. \[[@REF14]\]                 SCLC                              Chemotherapy                                    Prokinetics, NJ tube, TPN                         No clinical improvement
  Franco and Koulaeva \[[@REF15]\]           Pancreatic neuroendocrine tumor   Not a candidate for chemotherapy/radiotherapy   Prokinetics, IV erythromycin, TPN                 Symptoms improved with IV erythromycin which was later transitioned to PO erythromycin.
  Pardi et al. \[[@REF4]\]                   SCLC                              Not reported                                    Domperidone and jejunostomy tube                  Not reported
  Ghoshal et al. \[[@REF16]\]                Cholangiocarcinoma                Not reported                                    Dietary modification, prokinetics, NJ tube, TPN   Patient passed away six months after the onset of GI symptoms.
  Bernardis et al. \[[@REF17]\]              Leiomyosarcoma                    Surgical resection                              Antiemetics, prokinetics                          Symptoms improved after resection.
  Liang et al. \[[@REF18]\]                  SCLC                              Chemotherapy                                    TPN, surgical exploration                         No improvement. Passed nine months after diagnosis of cancer.
  Lautenbach and Lichtenstein \[[@REF19]\]   Leiomyosarcoma                    Surgical resection                              Prokinetics                                       Symptoms improved after resection.
  Nguyen-tat et al. \[[@REF3]\]              SCLC                              Chemotherapy                                    Prokinetics, jejunostomy tube                     No clinical improvement.
  Caras et al. \[[@REF20]\]                  Pancreatic adenocarcinoma         Chemotherapy and radiotherapy                   Antiemetics, prokinetics                          Symptoms improved initially with treatment but patient passed away eight months after diagnosis.
  Chinn and Schuffler Case 1 \[[@REF5]\]     SCLC                              Cancer found post-mortem                        Prokinetics                                       No clinical improvement. Patient passed away nine months after the onset of GI symptoms.
  Chinn and Schuffler Case 2 \[[@REF5]\]     SCLC                              Chemotherapy                                    Prokinetics                                       No clinical improvement. Patient passed away five months after the onset of GI symptoms.
  Chinn and Schuffler Case 3 \[[@REF5]\]     SCLC                              Chemotherapy                                    Prokinetics                                       No clinical improvement. Patient passed away six months after the onset of GI symptoms.
  Chinn and Schuffler Case 4 \[[@REF5]\]     Lung carcinoid                    Surgical resection                              Prokinetics                                       Symptoms improved with prokinetics and surgical resection. Patient was alive 57 months after the onset of GI symptoms.
  Chinn and Schuffler Case 5 \[[@REF5]\]     SCLC                              Cancer found post-mortem                        Prokinetics                                       No clinical improvement. Patient passed away four months after the onset of GI symptoms.
  Chinn and Schuffler Case 6 \[[@REF5]\]     SCLC                              Chemotherapy                                    Prokinetics                                       No clinical improvement. Patient passed away five months after the onset of GI symptoms.
  Chinn and Schuffler Case 7 \[[@REF5]\]     SCLC                              Chemotherapy                                    Prokinetics                                       Symptoms improved with prokinetics. Patient was alive 41 months after the onset of GI symptoms.
  ------------------------------------------ --------------------------------- ----------------------------------------------- ------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------

The population ranged in age from 20 to 87 years with a mean age of 63.9 years and there was a male to female ratio of 1:1.2. The majority of cases had an underlying small cell lung cancer diagnosis (14/22 cases), however cases of pulmonary carcinoid, cholangiocarcinoma, pancreatic neuroendocrine tumor, pancreatic adenocarcinoma, and leiomyosarcoma are also represented. In 19 cases, GI symptoms of dysmotility preceded the diagnosis of cancer, with an average of 6.4 months between onset of gastroparesis and the diagnosis of malignancy.

In our literature review, eight cases included testing for anti-Hu antibodies, of these seven were in the setting of small cell lung cancer (SCLC) and one was adenocarcinoma of the lung. The case of adenocarcinoma of the lung had a negative anti-Hu serology. In six out of the seven cases of SCLC with PG a positive anti-Hu antibody was seen. Anti-Hu antibodies have not been well studied in cases of PG outside of SCLC, in large part due to the rarity of the syndrome. Our review of the literature is consistent with the case series conducted by Lee et al. \[[@REF2]\] where they found that eight out of nine patients presenting to the Mayo Clinic with PG secondary to SCLC were found to have positive anti-Hu serology.

In our review, 14 cases underwent surgical resection or chemotherapy/radiotherapy to treat their cancer, and in six cases symptoms of gastroparesis improved or resolved after therapy.

Conclusions
===========

Paraneoplastic gastroparesis is a rare and challenging diagnosis, however accurate identification can have significant implications for patients. Symptoms of gastroparesis frequently present before the diagnosis of cancer in PG. The challenge of recognizing PG can be made less burdensome with serologic evaluation, though more studies are needed.

The authors have declared that no competing interests exist.

Consent was obtained by all participants in this study
